The panel was unanimous that Grail's Galleri is safe and divided six to four on whether it is effective, on evidence in which 287 of more than 35,000 people screened got a cancer signal and about 60 percent of those were diagnosed.
Perspective Coverage
3 publishers
- Builder
- Builder 22%
- Operator
- Operator 43%
- Investor
- Investor 35%
Reality
- Evidence62
- Adoption
- Not scored
- Hype gap+35
- Incentives55
- Confidence58
Distinct gut microbes mark colorectal and breast cancers diagnosed at 50 or younger
Mayo Clinic researchers tie colorectal and breast cancers diagnosed at 50 or younger to distinct gut microbes, using stool from 1,364 patients. The signals give researchers named bacteria to test next, though the data cannot yet say whether those microbes drive early disease or follow from it.
Reality
- Evidence55
- Adoption
- Not scored
- Hype gap+5
- Incentives
- Not scored
- Confidence55
A RAS inhibitor wins FDA approval in metastatic pancreatic cancer at $39,800 a month
Revolution Medicines' daraxonrasib nearly doubled median overall survival in previously treated patients. Investors sat still anyway, because the unresolved variable is now what payers will absorb.
Reality
- Evidence70
- Adoption34
- Hype gap+16
- Incentives72
- Confidence61
A pancreatic pill proves pan-RAS is druggable. Lung and colon will price the claim
Rasonque roughly doubled median survival against a 6.7-month chemotherapy arm in a cancer where nearly every tumor carries a KRAS mutation. Neither condition repeats in the bigger indications.
Reality
- Evidence60
- Adoption52
- Hype gap+27
- Incentives74
- Confidence50
A cancer charity sunsets its liquor gala; the courts are less consistent
The American Cancer Society killed its October Wine and Spirits Gala under two months after STAT put a $22 million floor on alcohol-industry giving. Judges split the same week on patient records.
Reality
- Evidence74
- Adoption28
- Hype gap+14
- Incentives62
- Confidence66